<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165721</url>
  </required_header>
  <id_info>
    <org_study_id>170088</org_study_id>
    <secondary_id>17-C-0088</secondary_id>
    <nct_id>NCT03165721</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer</brief_title>
  <official_title>A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Wild-type gastrointestinal stromal tumor (GIST) is a cancer in the esophagus, stomach, or&#xD;
      intestines. It does not respond well to standard chemotherapy or radiation therapy. Most&#xD;
      people with GIST are treated with imatinib. But it may not work in many children with GIST.&#xD;
      Researchers think the drug SGI-110 may help treat people with GIST, pheochromocytoma and&#xD;
      paraganglioma (PHEO/PGL), or kidney cancer related to hereditary leiomyomatosis and renal&#xD;
      cell carcinoma (HLRCC).&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To learn if SGI-110 causes GIST tumors to shrink or slows their growth. Also to test how it&#xD;
      acts in the body.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 12 and older who have GIST, PHEO/PGL, or HLRCC that has not responded to other&#xD;
      treatments&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with:&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Urine tests&#xD;
&#xD;
        -  Computed tomography (CT) or magnetic resonance imaging (MRI), or fluorodeoxyglucose&#xD;
           (FDG)-positron emission tomography (PET) scan: A machine takes pictures of the body.&#xD;
&#xD;
        -  Blood tests&#xD;
&#xD;
      Participants will be injected with SGI-110 under the skin each day for 5 days. This cycle&#xD;
      will repeat every 28 days. The cycles repeat until their side effects get too bad or their&#xD;
      cancer gets worse.&#xD;
&#xD;
      Participants will have tests throughout study:&#xD;
&#xD;
        -  Physical exam and blood and urine tests before each cycle&#xD;
&#xD;
        -  Blood tests on days 1, 7, 14, and 28 of the first cycle.&#xD;
&#xD;
        -  Scans before cycle 1 and then every other cycle.&#xD;
&#xD;
        -  Questionnaires about their pain and quality of life&#xD;
&#xD;
        -  Tumor biopsy for those 18 and older: A needle removes a small piece of tumor.&#xD;
&#xD;
      After they stop treatment, participants will have a final visit. This includes an evaluation&#xD;
      of their health, pain, and quality of life.&#xD;
&#xD;
      ...&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
        -  Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH) complex or&#xD;
           fumarate hydratase (FH), has been identified as a mechanism of tumorigenesis in subsets&#xD;
           of gastrointestinal stromal tumor (GIST), pheochromocytoma and paraganglioma (PHEO/PGL),&#xD;
           and renal cell carcinoma.&#xD;
&#xD;
        -  Deoxyribonucleic acid (DNA) hypermethylation has been demonstrated in these cancers.&#xD;
           Loss of activity of SDH or FH leads to accumulation of the metabolites succinate and&#xD;
           fumarate, respectively. Succinate and fumarate act as inhibitors of a broad array of&#xD;
           alpha-ketoglutarate dependent dioxygenases. The Ten-eleven Translocation (TET) family of&#xD;
           alphaKG-dependent dioxygenase enzymes convert 5-methylcytosine to&#xD;
           5-hydroxymethylcytosine leading to DNA demethylation. Inhibition of these enzymes due to&#xD;
           SDH and FH deficiency causes DNA hypermethylation and has been verified in preclinical&#xD;
           models.&#xD;
&#xD;
        -  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the&#xD;
           gastrointestinal tract, resistant to cytotoxic chemotherapy and radiation therapy. KIT&#xD;
           and Platelet Derived Growth Factor Receptor Alpha (PDGFRA) mutations have been&#xD;
           identified as tumor initiating events in 85% of adult patients with GIST and these&#xD;
           tumors are responsive to the tyrosine kinase inhibitor, Imatinib. In pediatric patients,&#xD;
           however, 85% of GISTs lack KIT and PDGFRA mutations (wild-type) and imatinib is not&#xD;
           effective.&#xD;
&#xD;
        -  Recent work in the Pediatric and Wild-Type (wt) GIST Clinic at the National Cancer&#xD;
           Institute (NCI) led to the identification of succinate dehydrogenase (SDH) deficiency in&#xD;
           approximately 90% of wildtype GIST.&#xD;
&#xD;
        -  In addition to wild-type GIST, SDH deficiency is also present in 30% of pheochromocytoma&#xD;
           and paraganglioma (PHEO/PGL) and a subset of renal carcinoma. Loss of succinate&#xD;
           dehydrogenase complex iron sulfur subunit B (SDHB) protein expression is seen in&#xD;
           PHEO/PGL and wtGIST either due to mutation in SDH subunit genes or hypermethylation of&#xD;
           the SDHC promoter region.&#xD;
&#xD;
        -  Mutations leading to loss of function of FH have been identified in PHEO/PGL as well as&#xD;
           type II papillary renal cell carcinoma in patients with hereditary leiomyomatosis and&#xD;
           renal cell cancer (HLRCC). An FH-deficient paraganglioma had DNA hypermethylation as&#xD;
           demonstrated by array and immunohistochemistry showed increased 5hmC levels in&#xD;
           paragangliomas and pheochromocytomas.&#xD;
&#xD;
        -  SGI-110 is a small molecule derivative of decitabine that acts as a DNA&#xD;
           methyltransferase (DNMT) inhibitor and is resistant to inactivation by cytidine&#xD;
           deaminase, hence may thus have a more favorable pharmacokinetic profile compared to&#xD;
           decitabine. Subcutaneously administered SGI-110 is gradually converted to decitabine&#xD;
           resulting in prolonged exposure with a several fold increase in apparent T1/2 compared&#xD;
           to intravenous decitabine. SGI-110 has been demonstrated in preclinical models to induce&#xD;
           a dose-dependent decrease in global DNA methylation and up-regulate expression of&#xD;
           specific genes including Melanoma-associated antigen 1 (MAGE-A1) and New York esophageal&#xD;
           squamous cell carcinoma 1 (NY-ESO-1) through decreased methylation.&#xD;
&#xD;
        -  We are proposing a phase II trial with SGI-110 in these SDH-deficient and fumarate&#xD;
           hydratase (FH)-deficient tumors.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      -To assess the clinical activity of SGI-110 in patients with wt-GIST, SDH-deficient PHEO/PGL,&#xD;
      and HLRCC-associated renal cell carcinoma (RCC) using Response Evaluation Criteria in Solid&#xD;
      Tumors (RECIST).&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Adults and children (greater than or equal to 12 years of age) with wt-type GIST, SDH&#xD;
           deficient PHEO/PGL, or HLRCC-associated RCC and measurable disease will be eligible.&#xD;
&#xD;
        -  Newly diagnosed patients with PHEO/PGL or HLRCC-associated RCC with localized,&#xD;
           resectable disease will not be eligible. Patients with PHEO/PGL or HLRCC-associated RCC&#xD;
           with unresectable localized disease and/or metastatic disease will be eligible.&#xD;
&#xD;
        -  Newly diagnosed patients with wt-GIST with completely resectable disease will not be&#xD;
           eligible. Patients with wt-GIST with metastatic disease and/or residual or recurrent&#xD;
           tumor following surgical debulking will be eligible&#xD;
&#xD;
        -  Patients with wt-GIST or HLRCC-associated RCC who have not previously received systemic&#xD;
           therapy are eligible as there are no standard chemotherapy regimens known to be&#xD;
           effective for these cancers.&#xD;
&#xD;
        -  Must have adequate performance status, may not be pregnant or breastfeeding, and must&#xD;
           have adequate major organ function.&#xD;
&#xD;
        -  No history of severe or uncontrolled inter-current illness including, but not limited&#xD;
           to, ongoing or active infection, symptomatic cardiovascular or pulmonary disease will be&#xD;
           excluded.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This is a single site, open label, phase II study using a small optimal two-stage design&#xD;
           to evaluate the clinical response in three groups of patients:&#xD;
&#xD;
             1. wild-type GIST (GIST without KIT or PDGFRA mutation)&#xD;
&#xD;
             2. PHEO/PGL in patients with germline SDH subunit mutation, or&#xD;
&#xD;
             3. RCC associated with HLRCC&#xD;
&#xD;
        -  SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
           to the three groups of patients.&#xD;
&#xD;
        -  SGI-110 activity will be assessed by imaging response of measurable disease using&#xD;
           Response Evaluation Criteria in Solid Tumors (RECIST)v1.1, using computed tomography&#xD;
           (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET).&#xD;
&#xD;
        -  Patients will be closely monitored for development of toxicity with regular physical&#xD;
           examinations and laboratory evaluations. Toxicity will be graded using version 4.0 of&#xD;
           the National Cancer Institute (NCI) Common Toxicity Criteria.&#xD;
&#xD;
        -  SGI-110 related toxicities greater than or equal to grade 3 will be considered treatment&#xD;
           limiting toxicities, unless they are reversible within 72 hours with supportive care.&#xD;
           Following recovery from toxicity up to 2 dose reductions will be allowed.&#xD;
&#xD;
        -  Initially 7 evaluable patients in each group (strata) will be enrolled and if 0 of the 7&#xD;
           have a response, then no further patients will be accrued in that strata. If 1 or more&#xD;
           the first 7 (14.3% or more) have a response, then accrual would continue until a total&#xD;
           of 21 patients have enrolled in that strata. If at least 3 responses (at least 14.3%)&#xD;
           are observed among the 21 evaluable patients, the agent should be considered worthy of&#xD;
           further testing in this disease.&#xD;
&#xD;
        -  Enrolling 2 patients/month, it is estimated to require 3 years to complete accrual to a&#xD;
           maximum of 70 patients, a maximum of 63 evaluable patients allowing for a small number&#xD;
           (7) of inevaluable patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed to enrollment due to low accrual.&#xD;
  </why_stopped>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">February 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>After the first 4 weeks, then every 8 weeks up to 65 weeks</time_frame>
    <description>Clinical activity of SGI-11 was assessed using the RECISTv1.1. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Distress From Baseline</measure>
    <time_frame>Baseline, end of cycle 4, and post therapy follow up, approximately 30 days after the final dose of study drug</time_frame>
    <description>Change in distress from baseline was assessed by The Distress Thermometer (DT) visual analog scale. An overall score is derived from specific physical, emotional and family issues identified by the participant to be stressful. No distress (0-4), moderate stress (5) and high distress (6-10).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Paraganglioma</condition>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Renal Neoplasms</condition>
  <condition>Pheochromocytoma</condition>
  <arm_group>
    <arm_group_label>Patients ≥ 12 Years of Age w/Wild-Type GIST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110 (guadecitabine)</intervention_name>
    <description>SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
    <arm_group_label>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</arm_group_label>
    <arm_group_label>Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE</arm_group_label>
    <arm_group_label>Patients ≥ 12 Years of Age w/Wild-Type GIST</arm_group_label>
    <other_name>guadecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Patients must:&#xD;
&#xD;
          -  Have recurrent or refractory/unresectable disease for which there is no known curative&#xD;
             therapy.&#xD;
&#xD;
             ---Wild type-gastrointestinal stromal tumors (GIST): Patients with recurrent or&#xD;
             progressive disease will be eligible. Newly diagnosed patients with resectable&#xD;
             localized disease will not be eligible. Newly diagnosed patients with metastatic&#xD;
             disease and newly diagnosed patients with residual tumor following surgical debulking&#xD;
             will be eligible.&#xD;
&#xD;
               -  Paraganglioma-Pheochromocytoma (PHEO/PGL): Patients with recurrent or progressive&#xD;
                  disease will be eligible. Newly diagnosed patients with PHEO/PGL that is&#xD;
                  metastatic at diagnosis and/or unresectable will be eligible Patients with&#xD;
                  PHEO/PGL with localized (non-metastatic), resectable disease will not be&#xD;
                  eligible.&#xD;
&#xD;
               -  Renal cell cancer associated with HLRCC: Patients with localized, resectable&#xD;
                  HLRCC-associated renal cell cancer will not be eligible. Patients with metastatic&#xD;
                  and/or unresectable Hereditary leiomyomatosis and renal cell cancer&#xD;
                  (HLRCC)-associated renal cell cancer will be eligible.&#xD;
&#xD;
          -  Have one of the following confirmed histologically, cytologically, or through&#xD;
             biochemical testing:&#xD;
&#xD;
               -  wild-type GIST (GIST without KIT or platelet derived growth factor receptor alpha&#xD;
                  (PDGFRA) mutation);&#xD;
&#xD;
               -  PHEO/PGL with a germline mutation in Succinate Dehydrogenase Complex Flavoprotein&#xD;
                  Subunit A (SDHA), Succinate Dehydrogenase Complex Flavoprotein Subunit B (SDHB),&#xD;
                  SDHC, or SDHD;&#xD;
&#xD;
                  --renal cell cancer associated with HLRCC.&#xD;
&#xD;
          -  Testing will be performed in Clinical Laboratory Improvement Amendments (CLIA)&#xD;
             certified labs using genetic tests for KIT/PDGFRA and testing panels developed for&#xD;
             patients with PHEO/PGL. Results from outside labs will be accepted. Pathologic&#xD;
             diagnosis will be reviewed and verified at the Clinical Center.&#xD;
&#xD;
          -  Age: be greater than or equal to 12 years of age&#xD;
&#xD;
        Because there is no dosing or adverse event data currently available on the use of SGI-110&#xD;
        in children &lt; 18 year of age, children &lt; 12 years of age will be excluded from this study,&#xD;
        but may be eligible for future pediatric trials should the results of the study be&#xD;
        positive.&#xD;
&#xD;
        - Measurable disease:&#xD;
&#xD;
        Have measurable disease, defined as at least one lesion that can be accurately measured in&#xD;
        at least one dimension (longest diameter to be recorded for non-nodal lesions and short&#xD;
        axis for nodal lesions) as greater than or equal to 20 mm with conventional techniques or&#xD;
        as greater than 10 mm with spiral computed tomography (CT) scan.&#xD;
&#xD;
          -  Prior Therapy&#xD;
&#xD;
          -  Prior therapy requirements:&#xD;
&#xD;
             ---Wt-GIST: Because there are no standard chemotherapy regimens known to be effective&#xD;
             for wt-GIST, previously untreated participants are eligible.&#xD;
&#xD;
             --PHEO/PGL with germline SDH subunit mutation: 131I-MIBG in patients with MIBG avid&#xD;
             tumors or cytotoxic chemotherapy (cyclophosphamide, vincristine, and dacarbazine (CVD)&#xD;
             or temozolomide) is required prior to enrollment on this trial. However, patients who&#xD;
             have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to&#xD;
             receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by&#xD;
             the local investigator will also be eligible.&#xD;
&#xD;
             ---HLRCC-associated renal cell cancer: Because there are no standard chemotherapy&#xD;
             regimens known to be effective for HLRCC-associated renal cell cancer, previously&#xD;
             untreated participants are eligible.&#xD;
&#xD;
          -  Prior therapy wash-out period requirements&#xD;
&#xD;
             --Participants must be at least 4 weeks from prior surgical procedures and surgical&#xD;
             incisions must be healed.&#xD;
&#xD;
             ---Participants must have had their last fraction of external beam radiation therapy&#xD;
             at least 4 weeks prior to enrollment. Participants with prior radiation therapy must&#xD;
             be at least 4 weeks post therapy and have had progression of disease outside the&#xD;
             radiation port.&#xD;
&#xD;
               -  Participants must have had their last dose of cytotoxic chemotherapy at least 28&#xD;
                  days prior to enrollment, their last dose of biological therapy, such as&#xD;
                  biological response modifiers (e.g., cytokines), immunomodulatory agents,&#xD;
                  vaccines, differentiating agents, used to treat their cancer at least 28 days&#xD;
                  prior to enrollment, their last dose of a monoclonal antibody at least 28 days&#xD;
                  prior to enrollment, and their last dose of any investigational agent at least 28&#xD;
                  days prior to enrollment.&#xD;
&#xD;
               -  Participants must have recovered from the acute toxic effects of prior therapy to&#xD;
                  a grade 1 level prior to enrollment (does not apply to alopecia).&#xD;
&#xD;
          -  Performance Level: Eastern Cooperative Oncology Group (ECOG) performance status less&#xD;
             than or equal 2 or Karnofsky greater than or equal to 60% in patients greater than 16&#xD;
             years of age, Lansky greater than or equal to 60 for patients less than or equal to 16&#xD;
             years of age.&#xD;
&#xD;
          -  Have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  absolute neutrophil count greater than or equal to 1,500/mcL&#xD;
&#xD;
               -  platelets greater than or equal to 100,000/mcL&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) Serum glutamic oxaloacetic&#xD;
                  transaminase(SGOT)/Alanine aminotransferase (ALT) Serum glutamic pyruvic&#xD;
                  transaminase(SGPT) less than or equal to 2.5 x institutional upper limit of&#xD;
                  normal&#xD;
&#xD;
               -  creatinine within normal institutional limits&#xD;
&#xD;
        OR&#xD;
&#xD;
        ----creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with&#xD;
        creatinine levels above institutional normal.&#xD;
&#xD;
        -Birth Control:&#xD;
&#xD;
        The effects of SGI-110 on the developing human fetus are unknown. For this reason and&#xD;
        because decitabine is known to be teratogenic, women of child-bearing potential and men&#xD;
        must agree to use adequate contraception (hormonal or barrier method of birth control;&#xD;
        abstinence) prior to study entry and for the duration of study participation, and for 6&#xD;
        months following participation. Should a woman become pregnant or suspect she is pregnant&#xD;
        while she or her partner is participating in this study, she should inform her treating&#xD;
        physician immediately.&#xD;
&#xD;
        -Ability of subject or legal guardians (if the patient is &lt;18 years old) to understand and&#xD;
        the willingness to sign a written informed consent document.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients with any one the following will be excluded:&#xD;
&#xD;
          -  Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor,&#xD;
             immunotherapy, or biologic therapy, including investigational agents for their&#xD;
             disease.&#xD;
&#xD;
          -  History of allergic reactions to SGI-110 or decitabine.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic&#xD;
             pulmonary disease or psychiatric illness/social situations that would limit compliance&#xD;
             with study requirements.&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
        Pregnant women are excluded from this study because SGI-110 is a derivative of decitabine&#xD;
        which has the potential for teratogenic or abortifacient effects. Because there is an&#xD;
        unknown but potential risk for adverse events in nursing infants secondary to treatment of&#xD;
        the mother with SGI-110, breastfeeding should be discontinued if the mother is treated with&#xD;
        SGI-110.&#xD;
&#xD;
        These potential risks may also apply to other agents used in this study.&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease, active infection, active&#xD;
             bleeding diatheses, or renal transplant, including any patient known to have hepatitis&#xD;
             B, hepatitis C, or human immunodeficiency virus (HIV) will be excluded. Patients with&#xD;
             HIV who have adequate cluster of differentiation 4 (CD4) count, not requiring&#xD;
             antiretroviral medication, may be enrolled.&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, may not be able to comply with the&#xD;
             safety monitoring requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Glod, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2017-C-0088.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>April 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>John Glod</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Renal Cancer</keyword>
  <keyword>DNA Hypermethylation</keyword>
  <keyword>Gastrointestinal Stromal Tumors</keyword>
  <keyword>DNA Methyltransferase (DNMT) Inhibitor</keyword>
  <keyword>Succinate Dehydrogenase (SDH) Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guadecitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03165721/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Standard</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03165721/ICF_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Assent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03165721/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="P2">
          <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="P3">
          <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="B2">
          <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="B3">
          <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.86" spread="16.03"/>
                    <measurement group_id="B2" value="41" spread="0"/>
                    <measurement group_id="B3" value="23" spread="0"/>
                    <measurement group_id="B4" value="34.22" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Clinical activity of SGI-11 was assessed using the RECISTv1.1. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.</description>
        <time_frame>After the first 4 weeks, then every 8 weeks up to 65 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>Clinical activity of SGI-11 was assessed using the RECISTv1.1. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Distress From Baseline</title>
        <description>Change in distress from baseline was assessed by The Distress Thermometer (DT) visual analog scale. An overall score is derived from specific physical, emotional and family issues identified by the participant to be stressful. No distress (0-4), moderate stress (5) and high distress (6-10).</description>
        <time_frame>Baseline, end of cycle 4, and post therapy follow up, approximately 30 days after the final dose of study drug</time_frame>
        <population>n=6 for the first Group at the end of cycle 4; this time data at this time point was not collected for one participant. Participant off therapy due to progressive disease (PD) at the end of cycle 1 for the third Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distress From Baseline</title>
          <description>Change in distress from baseline was assessed by The Distress Thermometer (DT) visual analog scale. An overall score is derived from specific physical, emotional and family issues identified by the participant to be stressful. No distress (0-4), moderate stress (5) and high distress (6-10).</description>
          <population>n=6 for the first Group at the end of cycle 4; this time data at this time point was not collected for one participant. Participant off therapy due to progressive disease (PD) at the end of cycle 1 for the third Group.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post therapy follow up, approximately 30 days after the final dose of study drug</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Progression Free Survival Probability at 6 Months</title>
        <description>Time interval from start of treatment to documented evidence of disease progression. Progression were evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
        <time_frame>6 months</time_frame>
        <population>Patient's progressed at 3.9 months and 1.1 month respectively, for the second and third groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Probability at 6 Months</title>
          <description>Time interval from start of treatment to documented evidence of disease progression. Progression were evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
          <population>Patient's progressed at 3.9 months and 1.1 month respectively, for the second and third groups.</population>
          <units>Percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="33.4" upper_limit="97.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Progression Free Survival (PFS) Probability at 12 Months</title>
        <description>Time interval from start of treatment to documented evidence of disease progression. Progression were evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions</description>
        <time_frame>12 months</time_frame>
        <population>Patient's progressed at 3.9 months and 1.1 month respectively, for the second and third groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) Probability at 12 Months</title>
          <description>Time interval from start of treatment to documented evidence of disease progression. Progression were evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions</description>
          <population>Patient's progressed at 3.9 months and 1.1 month respectively, for the second and third groups.</population>
          <units>Percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" lower_limit="13.2" upper_limit="82.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Overall Survival (OS)</title>
        <description>Time from treatment start date until date of death or date last known alive.</description>
        <time_frame>Time from treatment start date until date of death or date last known alive, up to approximately 3 years, 2 months.</time_frame>
        <posting_date>02/2026</posting_date>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health)</title>
        <description>Quality of Life (QOL) was assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health. Overall scores were derived from five quality of life domains: physical function, pain interference, fatigue, emotional health and social health). T-Score distributions are standardized so that a score of 50 represents the mean for the US general population with a standard deviation around that mean of 10 points.</description>
        <time_frame>Baseline, at the end of cycle 4, and post therapy follow up, approximately 30 days after the final dose of study drug</time_frame>
        <population>Participant off therapy due to progressive disease (PD) at the end of cycle 1 in the third Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health)</title>
          <description>Quality of Life (QOL) was assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health. Overall scores were derived from five quality of life domains: physical function, pain interference, fatigue, emotional health and social health). T-Score distributions are standardized so that a score of 50 represents the mean for the US general population with a standard deviation around that mean of 10 points.</description>
          <population>Participant off therapy due to progressive disease (PD) at the end of cycle 1 in the third Group.</population>
          <units>t-score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" lower_limit="40.5" upper_limit="51.3"/>
                    <measurement group_id="O2" value="54.1"/>
                    <measurement group_id="O3" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="40.6" upper_limit="52.4"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Participant off therapy due to progressive disease (PD) at the end of cycle 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post therapy follow up, approximately 30 days after the final dose of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="37.5" upper_limit="50.9"/>
                    <measurement group_id="O2" value="54.1"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Participant off therapy due to progressive disease (PD) at the end of cycle 1.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mental Health)</title>
        <description>Quality of Life (QOL) was assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mental Health. Overall scores were derived from five quality of life domains: physical function, pain interference, fatigue, emotional health and social health). T-Score distributions are standardized so that a score of 50 represents the mean for the US general population with a standard deviation around that mean of 10 points.</description>
        <time_frame>Baseline, at the end of cycle 4, and post therapy follow up, approximately 30 days after the final dose of study drug</time_frame>
        <population>n=6 for the first Group at the end of cycle 4; this time data at this time point was not collected for one participant. Participant off treatment at cycle 1 due to progressive disease (PD) in the third Group.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mental Health)</title>
          <description>Quality of Life (QOL) was assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mental Health. Overall scores were derived from five quality of life domains: physical function, pain interference, fatigue, emotional health and social health). T-Score distributions are standardized so that a score of 50 represents the mean for the US general population with a standard deviation around that mean of 10 points.</description>
          <population>n=6 for the first Group at the end of cycle 4; this time data at this time point was not collected for one participant. Participant off treatment at cycle 1 due to progressive disease (PD) in the third Group.</population>
          <units>t-score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" lower_limit="39.7" upper_limit="46.7"/>
                    <measurement group_id="O2" value="41.1"/>
                    <measurement group_id="O3" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="41.9" upper_limit="50.1"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post therapy follow up, approximately 30 days after the final dose of study drug</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="36.8" upper_limit="45.6"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</title>
        <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approx. 1 mos and 5 days for the Gastrointestinal stromal tumor (GIST) group; 3 mos and 25 days for the Pheochromocytoma/Paraganglioma (Pheo/PGL) group;and 30 mos and 2 days for the Renal Cell Cancer group.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O2">
            <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
          <group group_id="O3">
            <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
            <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</title>
          <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Pharmacokinetics of Guadecitabine (SGI-110) in All Patients</title>
        <description>Active metabolite (decitabine) will be assayed in plasma.</description>
        <time_frame>Prior to first dose in cycle 1 and at 0.5 hour (+/- 15 minutes), 1 hour (+/- 15 minutes), 2 hour (+/-30 minutes), 4 hour (+/- 30 minutes), 6 hour (+/- 1 hour) and 24 hours (+/- 2 hours) after the first dose of drug in Cycle 1.</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Pharmacodynamics</title>
        <description>Long interspersed nuclear element -1 (LINE-1) demethylation in peripheral blood mononuclear cells (PBMC) using pyrosequencing and urine and plasma glycolytic metabolites.</description>
        <time_frame>Baseline and day 14 of cycle 1.</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 1 month and 5 days for the Gastrointestinal stromal tumor (GIST) group, 3 months and 25 days for the Pheochromocytoma and Paraganglioma (Pheo/PGL) group, and 30 months and 2 days for the Renal Cell Cancer group.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients ≥ 12 Years of Age w/Wild-Type GIST</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Gastrointestinal stromal tumor (GIST)&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="E2">
          <title>Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
        <group group_id="E3">
          <title>Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca</title>
          <description>SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle&#xD;
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca&#xD;
SGI-110 (guadecitabine): SGI-110 will be administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, Tumor debulking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flashing lights</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, Feeling warm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, Herpes simplex reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Investigations - Other, Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, Muscle cramp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Movements involuntary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, R. arm Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Glod</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>240-760-6194</phone>
      <email>john.glod@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

